S&P 500   3,855.12 (+0.36%)
DOW   30,958.40 (-0.12%)
QQQ   326.83 (+0.43%)
AAPL   142.64 (+2.57%)
MSFT   228.62 (+1.18%)
FB   277.58 (+1.12%)
GOOGL   1,886.86 (-0.30%)
AMZN   3,299.60 (+0.22%)
TSLA   872.90 (+3.10%)
NVDA   543.86 (-0.85%)
BABA   261.33 (+1.05%)
CGC   32.60 (-3.55%)
GE   10.97 (-1.26%)
MU   81.09 (-1.45%)
AMD   93.87 (+1.16%)
NIO   59.82 (-3.44%)
T   29.11 (+0.62%)
F   11.21 (-2.69%)
ACB   10.15 (-4.69%)
BA   202.46 (-1.64%)
DIS   171.71 (-0.62%)
NFLX   556.77 (-1.49%)
GILD   68.00 (+1.58%)
S&P 500   3,855.12 (+0.36%)
DOW   30,958.40 (-0.12%)
QQQ   326.83 (+0.43%)
AAPL   142.64 (+2.57%)
MSFT   228.62 (+1.18%)
FB   277.58 (+1.12%)
GOOGL   1,886.86 (-0.30%)
AMZN   3,299.60 (+0.22%)
TSLA   872.90 (+3.10%)
NVDA   543.86 (-0.85%)
BABA   261.33 (+1.05%)
CGC   32.60 (-3.55%)
GE   10.97 (-1.26%)
MU   81.09 (-1.45%)
AMD   93.87 (+1.16%)
NIO   59.82 (-3.44%)
T   29.11 (+0.62%)
F   11.21 (-2.69%)
ACB   10.15 (-4.69%)
BA   202.46 (-1.64%)
DIS   171.71 (-0.62%)
NFLX   556.77 (-1.49%)
GILD   68.00 (+1.58%)
S&P 500   3,855.12 (+0.36%)
DOW   30,958.40 (-0.12%)
QQQ   326.83 (+0.43%)
AAPL   142.64 (+2.57%)
MSFT   228.62 (+1.18%)
FB   277.58 (+1.12%)
GOOGL   1,886.86 (-0.30%)
AMZN   3,299.60 (+0.22%)
TSLA   872.90 (+3.10%)
NVDA   543.86 (-0.85%)
BABA   261.33 (+1.05%)
CGC   32.60 (-3.55%)
GE   10.97 (-1.26%)
MU   81.09 (-1.45%)
AMD   93.87 (+1.16%)
NIO   59.82 (-3.44%)
T   29.11 (+0.62%)
F   11.21 (-2.69%)
ACB   10.15 (-4.69%)
BA   202.46 (-1.64%)
DIS   171.71 (-0.62%)
NFLX   556.77 (-1.49%)
GILD   68.00 (+1.58%)
S&P 500   3,855.12 (+0.36%)
DOW   30,958.40 (-0.12%)
QQQ   326.83 (+0.43%)
AAPL   142.64 (+2.57%)
MSFT   228.62 (+1.18%)
FB   277.58 (+1.12%)
GOOGL   1,886.86 (-0.30%)
AMZN   3,299.60 (+0.22%)
TSLA   872.90 (+3.10%)
NVDA   543.86 (-0.85%)
BABA   261.33 (+1.05%)
CGC   32.60 (-3.55%)
GE   10.97 (-1.26%)
MU   81.09 (-1.45%)
AMD   93.87 (+1.16%)
NIO   59.82 (-3.44%)
T   29.11 (+0.62%)
F   11.21 (-2.69%)
ACB   10.15 (-4.69%)
BA   202.46 (-1.64%)
DIS   171.71 (-0.62%)
NFLX   556.77 (-1.49%)
GILD   68.00 (+1.58%)
Log in
NYSE:RDY

Dr. Reddy's Laboratories Stock Forecast, Price & News

$69.39
+0.56 (+0.81 %)
(As of 01/25/2021 03:44 PM ET)
Add
Compare
Today's Range
$69.17
Now: $69.39
$69.57
50-Day Range
$66.01
MA: $70.04
$73.08
52-Week Range
$33.33
Now: $69.39
$73.50
Volume5,859 shs
Average Volume156,093 shs
Market Capitalization$11.50 billion
P/E Ratio57.35
Dividend Yield0.39%
Beta0.41
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy

MarketRank

Overall MarketRank

1.25 out of 5 stars

Medical Sector

746th out of 1,922 stocks

Pharmaceutical Preparations Industry

378th out of 771 stocks

Analyst Opinion: 1.3Community Rank: 2.1Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone91-40-4900-2900
Employees21,650
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.32 billion
Cash Flow$3.67 per share
Book Value$12.41 per share

Profitability

Net Income$259 million

Miscellaneous

Market Cap$11.50 billion
Next Earnings Date1/29/2021 (Confirmed)
OptionableOptionable
$69.39
+0.56 (+0.81 %)
(As of 01/25/2021 03:44 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDY News and Ratings via Email

Sign-up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Dr. Reddy's Laboratories (NYSE:RDY) Frequently Asked Questions

How has Dr. Reddy's Laboratories' stock price been impacted by Coronavirus?

Dr. Reddy's Laboratories' stock was trading at $40.17 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDY stock has increased by 72.3% and is now trading at $69.23.
View which stocks have been most impacted by COVID-19
.

Is Dr. Reddy's Laboratories a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Dr. Reddy's Laboratories stock.
View analyst ratings for Dr. Reddy's Laboratories
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Dr. Reddy's Laboratories?

Wall Street analysts have given Dr. Reddy's Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dr. Reddy's Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO?

528 employees have rated Dr. Reddy's Laboratories CEO G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among Dr. Reddy's Laboratories' employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Dr. Reddy's Laboratories' next earnings date?

Dr. Reddy's Laboratories is scheduled to release its next quarterly earnings announcement on Friday, January 29th 2021.
View our earnings forecast for Dr. Reddy's Laboratories
.

How can I listen to Dr. Reddy's Laboratories' earnings call?

Dr. Reddy's Laboratories will be holding an earnings conference call on Friday, January 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Dr. Reddy's Laboratories' earnings last quarter?

Dr. Reddy's Laboratories Limited (NYSE:RDY) issued its quarterly earnings results on Wednesday, October, 28th. The company reported $0.62 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.12. The firm earned $666 million during the quarter. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 16.33% and a net margin of 8.23%.
View Dr. Reddy's Laboratories' earnings history
.

How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories announced an annual dividend on Thursday, July 9th. Stockholders of record on Friday, January 1st will be paid a dividend of $0.3304 per share on Friday, July 10th. This represents a yield of 0.5%. The ex-dividend date is Friday, July 10th. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.27.
View Dr. Reddy's Laboratories' dividend history
.

Is Dr. Reddy's Laboratories a good dividend stock?

Dr. Reddy's Laboratories pays an annual dividend of $0.27 per share and currently has a dividend yield of 0.39%. The dividend payout ratio of Dr. Reddy's Laboratories is 9.68%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 11.11% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.
View Dr. Reddy's Laboratories' dividend history.

What price target have analysts set for RDY?

4 brokers have issued 1 year target prices for Dr. Reddy's Laboratories' stock. Their forecasts range from $53.00 to $53.00. On average, they expect Dr. Reddy's Laboratories' share price to reach $53.00 in the next twelve months. This suggests that the stock has a possible downside of 23.4%.
View analysts' price targets for Dr. Reddy's Laboratories
or view Wall Street analyst' top-rated stocks.

Who are some of Dr. Reddy's Laboratories' key competitors?

What other stocks do shareholders of Dr. Reddy's Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), Vedanta (VEDL), HDFC Bank (HDB), Alibaba Group (BABA), GlaxoSmithKline (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE).

Who are Dr. Reddy's Laboratories' key executives?

Dr. Reddy's Laboratories' management team includes the following people:
  • Mr. Gunupati Venkateswara Prasad B.E., Co-Chairman, MD & Member of Management Council (Age 60)
  • Mr. Kallam Satish Reddy, Chairman & Member of the Management Council (Age 53)
  • Mr. Erez Israeli M.B.A., CEO & Member of the Management Council (Age 52)
  • Mr. Deepak Sapra M.B.A., Sr. VP, Global Head PSAI Bus. & Member of Management Council (Age 45)
  • Mr. M. V. Ramana M.B.A., MBA, CEO of Branded Markets - India & Emerging Countries and Member of Management Council (Age 51)
  • Mr. Ganadhish Kamat, Exec. VP, Global Head of Quality & Member of Management Council (Age 57)
  • Dr. Anil Namboodiripad, Sr. VP, Head of Proprietary Products, Head of Promius Pharma & Member of Management Council (Age 53)
  • Ms. Archana Bhaskar B.Sc., M.B.A., EVP, Head of Corp. Communications, Chief HR Officer & Member of Management Council (Age 53)
  • Mr. Sauri Gudlavalleti B.Tech., Sr. VP, Global Head of Integrated Product Devel. Organization & Member of Management Council (Age 42)
  • Mr. Yugandhar Puvvala M.B.A., Sr. VP, Global Head Global Supply Chain & Member of Management Council (Age 49)

What is Dr. Reddy's Laboratories' stock symbol?

Dr. Reddy's Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "RDY."

Who are Dr. Reddy's Laboratories' major shareholders?

Dr. Reddy's Laboratories' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Portland Hill Asset Management Ltd (0.01%), Ritholtz Wealth Management (0.01%), Crossmark Global Holdings Inc. (0.01%), JustInvest LLC (0.01%) and QP Wealth Management LLC (0.00%).

Which institutional investors are selling Dr. Reddy's Laboratories stock?

RDY stock was sold by a variety of institutional investors in the last quarter, including QP Wealth Management LLC, and Portland Hill Asset Management Ltd.

Which institutional investors are buying Dr. Reddy's Laboratories stock?

RDY stock was bought by a variety of institutional investors in the last quarter, including Ritholtz Wealth Management, Crossmark Global Holdings Inc., and JustInvest LLC.

How do I buy shares of Dr. Reddy's Laboratories?

Shares of RDY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Dr. Reddy's Laboratories' stock price today?

One share of RDY stock can currently be purchased for approximately $69.23.

How big of a company is Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories has a market capitalization of $11.47 billion and generates $2.32 billion in revenue each year. The company earns $259 million in net income (profit) each year or $2.79 on an earnings per share basis. Dr. Reddy's Laboratories employs 21,650 workers across the globe.

What is Dr. Reddy's Laboratories' official website?

The official website for Dr. Reddy's Laboratories is www.drreddys.com.

How can I contact Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories' mailing address is 8-2-337 ROAD NO.3 BANJARA HILLS, HYDERABAD K7, 500-034. The company can be reached via phone at 91-40-4900-2900 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.